NCT06110676View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of LZM012

PHASE3RecruitingINTERVENTIONAL
Enrollment

918

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

June 30, 2025

Conditions
Psoriasis
Interventions
BIOLOGICAL

LZM012

Recombinant anti-human IL-17A/F humanized monoclonal antibody injection

BIOLOGICAL

Secukinumab

Cosentyx

Trial Locations (1)

200000

RECRUITING

Huashan Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Livzon Pharmaceutical Group Inc.

INDUSTRY